Nexus Surgical & Medicare Intrinsic Value
Nexus Surgical & Medicare (NEXUSSURGL) median intrinsic value is ₹11.67 from 8 valuation models (range ₹4–₹27), vs current price ₹19.90 — -41.4% downside (Trading Above Calculated Value), margin of safety -70.5%. Also explore NEXUSSURGL share price charts to track price trends across different timeframes.
NEXUSSURGL Valuation Methods Summary — DCF, Graham Number & P/E
Nexus Surgical & Medicare intrinsic value across 8 models vs current price ₹19.90 — upside/downside and value range per method. Browse NEXUSSURGL complete financial statements for revenue, profit, balance sheet and cash flow data.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹13.20 | ₹10.56 - ₹15.84 | -33.7% | EPS: ₹1.10, Sector P/E: 12x |
| Book Value Method | asset | ₹3.98 | ₹3.58 - ₹4.38 | -80.0% | Book Value/Share: ₹1.67, P/B: 0.8x |
| Revenue Multiple Method | revenue | ₹11.67 | ₹10.50 - ₹12.84 | -41.4% | Revenue/Share: ₹11.67, P/S: 1.0x |
| EBITDA Multiple Method | earnings | ₹8.33 | ₹7.50 - ₹9.16 | -58.1% | EBITDA: ₹1.00Cr, EV/EBITDA: 5x |
| PEG Ratio Method | growth | ₹17.60 | ₹15.84 - ₹19.36 | -11.6% | EPS Growth: 20.0%, Fair P/E: 16.0x |
| Growth Adjusted P/E | growth | ₹9.46 | ₹8.51 - ₹10.41 | -52.5% | Revenue Growth: 15.0%, Adj P/E: 8.6x |
| ROE Based Valuation | profitability | ₹26.67 | ₹24.00 - ₹29.34 | +34.0% | ROE: 100.0%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹5.97 | ₹5.37 - ₹6.57 | -70.0% | EPS: ₹1.10, BVPS: ₹1.67 |
NEXUSSURGL Intrinsic Value vs Market Price — All Valuation Models
Nexus Surgical & Medicare fair value range ₹4–₹27 vs current market price ₹19.90 across 8 valuation models. For current market price and key ratios, visit Nexus Surgical & Medicare stock price NSE.
NEXUSSURGL Intrinsic Value Analysis — Undervalued or Overvalued?
Nexus Surgical & Medicare median intrinsic value ₹11.67, current price ₹19.90 — Trading Above Calculated Value by 41.4%, margin of safety -70.5%.
What is the intrinsic value of NEXUSSURGL?
Based on our comprehensive analysis using 8 different valuation methods, the estimated intrinsic value of Nexus Surgical & Medicare (NEXUSSURGL) is ₹11.67 (median value). With the current market price of ₹19.90, this represents a -41.4% variance from our estimated fair value.
The valuation range spans from ₹3.98 to ₹26.67, indicating ₹3.98 - ₹26.67.
Is NEXUSSURGL undervalued or overvalued?
Based on our multi-method analysis, Nexus Surgical & Medicare (NEXUSSURGL) appears to be trading above calculated value by approximately 41.4%.
NEXUSSURGL Financial Health — Key Ratios vs Industry Benchmarks
Nexus Surgical & Medicare financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Return on Equity | 100.0% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 12.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 3.50x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
NEXUSSURGL Cash Flow Quality — Operating & Free Cash Flow
Nexus Surgical & Medicare operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹1 Cr | ₹1 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2021 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |